TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7532395

Group type: EXPERIMENTAL
Intervention: Krypton laser treatment covering the foveal side with a narrow (< or = 100 microns) border of treatment to adjacent uninvolved retina.
Number of subjects: 353

Group type: COMPARATOR
Intervention: Krypton laser treatment with either some of the foveal side of the lesion left untreated or a wide border of treatment on the foveal side.
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Krypton laser treatment in eyes with neovascular lesions 200 to 500 microns from the center of the foveal avascular zone.
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Krypton laser treatment in eyes with lesions in either distance category in the Age‐Related Macular Degeneration Study.
Number of subjects: 353
Study: 2039294

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy and surgery (ES&S)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 52
Study: 31414974

Group type: EXPERIMENTAL
Intervention: Sufficient 25(OH)D levels (30-100 ng/mL)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Active vitiligo (associated with 25(OH)D deficiency ≤20 ng/mL)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Active vitiligo (associated with 25(OH)D insufficiency 21-29 ng/mL)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Stable vitiligo (associated with sufficient 25(OH)D levels 30-100 ng/mL)
Number of subjects: 101
Study: 31358008

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6 μg
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Number of subjects: 456

Group type: COMPARATOR
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: All treatments (BGF MDI, BFF MDI, GFF MDI)
Number of subjects: 456

Group type: COMPARATOR
Intervention: GFF MDI
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: BGF MDI
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: BFF MDI
Number of subjects: 456
Study: 27775484

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: MVPA by gender
Number of subjects: 540
Study: 25297681

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 60
Study: 24284096

Group type: EXPERIMENTAL
Intervention: Spectral analysis of blood plasma and cellular components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common techniques for detection (complete blood cell count, electrophoresis, high performance liquid chromatography)
Number of subjects: 0
Study: 20609546

Group type: EXPERIMENTAL
Intervention: Entertainment-based decision aid for breast cancer treatment along with usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 19741202

Group type: EXPERIMENTAL
Intervention: Adjustment for acute phase response using reported recent fever, AGP, and CRP
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Adjustment for acute phase response using reported recent fever and AGP
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Adjustment for acute phase response using CRP and/or AGP
Number of subjects: 690

Group type: COMPARATOR
Intervention: Reported recent fever alone
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: AGP
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: ZPP, TfR, and EPO
Number of subjects: 690
Study: 17878636

Group type: EXPERIMENTAL
Intervention: 50/50 premixed insulin lispro twice-daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: premixed human insulin (control group)
Number of subjects: 30
Study: 15520061

Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine (VRL) 30 mg/m2 on days 1 and 8 every 3 weeks plus hydrocortisone 40 mg/day
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine (VRL) plus hydrocortisone
Number of subjects: 414

Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 414
Study: 11573526

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group 1, 14 patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Spinal anaesthesia (group 2, 14 patients)
Number of subjects: 28
Study: 9930042

Group type: EXPERIMENTAL
Intervention: Nurse run clinics
Number of subjects: 1173
Study: 7528307

Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3381992

Group type: EXPERIMENTAL
Intervention: 0.5 g dipyrone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.0 g dipyrone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.5 g dipyrone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.0 g dipyrone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.5 g dipyrone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31780037

Group type: EXPERIMENTAL
Intervention: Peppermint gel applied three times a day for up to 14 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 150
Study: 28372983

Group type: EXPERIMENTAL
Intervention: Primary stenting with nitinol self-expanding stents
Number of subjects: 100

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 100
Study: 25586335

Group type: EXPERIMENTAL
Intervention: Intralesion abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak CK‐MB ≥300 IU/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CK‐MB measurement
Number of subjects: 0
Study: 24183034

Group type: EXPERIMENTAL
Intervention: CILA (Cookgas intubating laryngeal airway)
Number of subjects: 60

Group type: COMPARATOR
Intervention: FT-LMA (Fastrach intubating laryngeal mask airway)
Number of subjects: 60
Study: 21969009

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg/d)
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg/d)
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5-25 mg/d)
Number of subjects: 1761
Study: 18240352

Group type: EXPERIMENTAL
Intervention: Psychological intervention and medication
Number of subjects: 262

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 262
Study: 16538423

Group type: EXPERIMENTAL
Intervention: Infrared LED treatment (160 mW, 6 min, energy density 3.2 J/cm²)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group (sham irradiation)
Number of subjects: 32
Study: 14522567

Group type: EXPERIMENTAL
Intervention: Candesartan (C) or Enalapril (E)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Candesartan + Enalapril (C+E)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Candesartan + Metoprolol/Enalapril + Metoprolol (C+M/E+M)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Candesartan + Enalapril + Metoprolol (C+E+M)
Number of subjects: 426
Study: 11033843

Group type: EXPERIMENTAL
Intervention: BALF‐IL‐12 in sarcoidosis patients (41.3 +/- 43.9 pg/ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BALF‐IL‐12 in patients with active disease (71.3 +/- 54.3 pg/ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with number of T4 cells
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with total cell number, number and percentage of lymphocytes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with AM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with soluble ICAM‐1 levels in serum
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with soluble ICAM‐1 levels in BALF
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with ICAM‐1 expression of AM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AM of sarcoidosis (133 +/- 177 pg/ml)
Number of subjects: 36
Study: 8969784

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Carotid arteriography
Number of subjects: 721
Study: 1470243

Group type: EXPERIMENTAL
Intervention: 20% albumin solution plus crystalline infusion fluids
Number of subjects: 201

Group type: COMPARATOR
Intervention: Crystalline infusion fluids (control group)
Number of subjects: 201
Study: 6486078

Group type: EXPERIMENTAL
Intervention: Hypnotherapy for six months in addition to standard psychotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Psychotherapy (control group)
Number of subjects: 70
Study: 28873320

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (RR) - SHR group (n = 10) ingested standardized extract SHR-5 (432 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLC) group (n = 10)
Number of subjects: 20
Study: 29786343

Group type: EXPERIMENTAL
Intervention: Liquid wound dressing (treatment group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Iodophor (control group)
Number of subjects: 84
Study: 24842866

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m(2))
Number of subjects: 260

Group type: COMPARATOR
Intervention: 3-weekly cisplatin (100 mg/m(2))
Number of subjects: 260
Study: 22872200

Group type: EXPERIMENTAL
Intervention: Topical 1.5% azithromycin twice a day for three days
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month
Number of subjects: 67
Study: 20497146

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg od for 4 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg od for 4 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 134
Study: 25942521

Group type: EXPERIMENTAL
Intervention: Silver releasing lipido-colloid contact layer (CLS) dressing for 4 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control contact layer dressing (CL) for 4 weeks
Number of subjects: 102
Study: 15994710

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Lithium (target blood level: 0.6-1.2 meq/liter)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 431

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 431
Study: 12696839

Group type: EXPERIMENTAL
Intervention: Randomized interventions
Number of subjects: 7636

Group type: EXPERIMENTAL
Intervention: Interventions with a moderate number of sessions and a clear-cut behavioral focus
Number of subjects: 7636
Study: 10904055

Group type: EXPERIMENTAL
Intervention: Supine lower body negative pressure (LBNP) treadmill exercise at 1.0‐1.2 body wt (58 +/‐ 2 mmHg LBNP) for 40 min per day during bed rest
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control study (no exercise)
Number of subjects: 7
Study: 8604676

Group type: EXPERIMENTAL
Intervention: Psyllium-enriched cereal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control cereal
Number of subjects: 25
Study: 1994967

Group type: EXPERIMENTAL
Intervention: Eucalyptamint
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6383113

Group type: EXPERIMENTAL
Intervention: Aminophylline (60-120 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 32
Study: 28868169

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 92
Study: 25560711

Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg/d)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (preemptive therapy)
Number of subjects: 184
Study: 24103327

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 910

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 910
Study: 22002809

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 19844848

Group type: EXPERIMENTAL
Intervention: selumetinib (AstraZeneca plc)
Number of subjects: 0
Study: 17051503

Group type: EXPERIMENTAL
Intervention: Tipranavir plus ritonavir (TPV/r)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Ritonavir-boosted comparator protease inhibitor (CPI/r)
Number of subjects: 620
Study: 12626886

Group type: EXPERIMENTAL
Intervention: real phenotype (r‐PHT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: virtual phenotype (v‐PHT)
Number of subjects: 201
Study: 11340106

Group type: EXPERIMENTAL
Intervention: Beta-carotene capsules (6 mg daily for 60 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Puréed papaya (650 g daily for 60 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grated carrots (100 g daily for 60 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9387206

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg daily
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study: 10150446

Group type: EXPERIMENTAL
Intervention: Psycho-social tobacco use prevention intervention with refusal skills training
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 389
Study: 3305590

Group type: EXPERIMENTAL
Intervention: Topical folate (2 daily applications)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic folate (2 daily doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0
Study: 29473355

Group type: EXPERIMENTAL
Intervention: Auricular point sticking (12 hours before and after operation, at specific points, 1 minute each point, once every 2 hours)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Auricular point sticking
Number of subjects: 480
Study: 27899407

Group type: EXPERIMENTAL
Intervention: Navvus microcatheter
Number of subjects: 28

Group type: COMPARATOR
Intervention: Guidewire-only assessment
Number of subjects: 28
Study: 24727022

Group type: EXPERIMENTAL
Intervention: MK-5172 (100 mg) with peginterferon and ribavirin
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: MK-5172 (200 mg) with peginterferon and ribavirin
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: MK-5172 (400 mg) with peginterferon and ribavirin
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: MK-5172 (800 mg) with peginterferon and ribavirin
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (boceprevir and peginterferon and ribavirin)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: MK-5172 (400 mg) and (800 mg) with peginterferon and ribavirin
Number of subjects: 332
Study: 22952407

Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD) of the ilioinguinal nerve and inguinal ligament (n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Local anaesthetic (Bupivicaine) and steroid (Trimacinolone) injection (n=18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD) without randomisation (n=10)
Number of subjects: 36
Study: 21564061

Group type: EXPERIMENTAL
Intervention: Enactment-based sessions first, followed by therapist-centered sessions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Therapist-centered sessions first, followed by enactment-based sessions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enactment-based sessions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enactment-based sessions first
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both therapy process modalities
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enactment-based therapy process
Number of subjects: 16
Study: 19096190

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 17073160

Group type: EXPERIMENTAL
Intervention: Herceptin therapy
Number of subjects: 0
Study: 12698764

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 11121917

Group type: EXPERIMENTAL
Intervention: PCC (peppermint oil and caraway oil)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9373115

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA)
Number of subjects: 80
Study: 1547763

Group type: EXPERIMENTAL
Intervention: CBZ-CR 800 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBZ-CR 1200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBZ-CR 1600 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBZ-CR (all doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBZ-CR 800 mg, 1200 mg, 1600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2868481

Group type: EXPERIMENTAL
Intervention: Amobarbital
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Melperone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 45
Study: 29941416

Group type: EXPERIMENTAL
Intervention: Interactive visual displays
Number of subjects: 20

Group type: COMPARATOR
Intervention: Narrative abstracts
Number of subjects: 20
Study: 25893979

Group type: EXPERIMENTAL
Intervention: Topical ketoprofen in Transfersome(®) gel (IDEA‐033) plus oral placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Oral ketoprofen plus TDT 064
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: TDT 064 plus oral placebo
Number of subjects: 168
Study: 24485546

Group type: EXPERIMENTAL
Intervention: Accelerometer and Go4Life educational counseling for 24 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Accelerometer alone for the next 24 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: No intervention for the first 24 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Accelerometer and Go4Life based counseling for the next 24 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Older (80-93) subjects
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Increase in activity level
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Go4Life based exercise counseling program
Number of subjects: 49
Study: 21863462

Group type: EXPERIMENTAL
Intervention: Canadian Occupational Performance Measure (COPM)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 87
Study: 19968904

Group type: EXPERIMENTAL
Intervention: Dietary portfolio (nuts, plant sterols, viscous fibre, vegetable protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation statin cholesterol-lowering medication
Number of subjects: 0
Study: 18667204

Group type: EXPERIMENTAL
Intervention: EPA treatment (n=7503)
Number of subjects: 14981

Group type: COMPARATOR
Intervention: Control group (n=7478)
Number of subjects: 14981
Study: 16517383

Group type: EXPERIMENTAL
Intervention: Active manipulations
Number of subjects: 102

Group type: COMPARATOR
Intervention: Simulated manipulations
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 14738263

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 on day 1 and day 8 and Cisplatin 80 mg/m2 on day 1, administered every 3 weeks, followed by radiotherapy after chemotherapy.
Number of subjects: 20
Study: 10629570

Group type: EXPERIMENTAL
Intervention: Plasma PMN elastase concentration in PXE(+) group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Plasma PMN elastase concentration in PXE(-) group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Plasma PMN elastase concentration in control group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Plasma alpha1-PI concentration in PXE(+) group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Plasma alpha1-PI concentration in PXE(-) group
Number of subjects: 65
Study: 9184183

Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate 125 mg m(‐2) on days 1‐5 every 3 weeks, escalating to 175 mg m(‐2) from course 3 when possible
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral etoposide
Number of subjects: 17
Study: 1542832

Group type: EXPERIMENTAL
Intervention: Peptamen (PEP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vivonex TEN (VIV)
Number of subjects: 16
Study: 3891194

Group type: EXPERIMENTAL
Intervention: Potassium chloride preparation 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Potassium chloride preparation 2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31532520

Group type: EXPERIMENTAL
Intervention: 3-D virtual reality models during surgical planning
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual preoperative planning with computed tomography and/or magnetic resonance imaging only
Number of subjects: 92
Study: 28213673

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 45
Study: 25412591

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: T1DM girls
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: T1DM boys
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control boys
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control girls
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: T1DM group
Number of subjects: 73
Study: 24222839

Group type: EXPERIMENTAL
Intervention: Intravenous ivabradine (5 mg bolus over 30 s, followed by 5 mg infusion over 8 h)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intravenous ivabradine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 21695122

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 760